These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 22394588

  • 1. Sublingual apomorphine as a neuroendocrine probe.
    Brunerova L, Potockova J, Horacek J, Koprivova H, Rehula M, Andel M.
    Psychiatry Res; 2012 Jul 30; 198(2):297-9. PubMed ID: 22394588
    [Abstract] [Full Text] [Related]

  • 2. Central dopaminergic activity influences metabolic parameters in healthy men.
    Brunerova L, Potockova J, Horacek J, Suchy J, Andel M.
    Neuroendocrinology; 2013 Jul 30; 97(2):132-8. PubMed ID: 22947694
    [Abstract] [Full Text] [Related]

  • 3. Dopamine function in obsessive-compulsive disorder: growth hormone response to apomorphine stimulation.
    Brambilla F, Bellodi L, Perna G, Arancio C, Bertani A.
    Biol Psychiatry; 1997 Nov 15; 42(10):889-97. PubMed ID: 9359974
    [Abstract] [Full Text] [Related]

  • 4. A psychoncological study of lymphocyte subpopulations in relation to pleasure-related neurobiochemistry and sexual and spiritual profile to Rorschach's test in early or advanced cancer patients.
    Messina G, Lissoni P, Bartolacelli E, Tancini G, Villa S, Gardani GS, Brivio F.
    J Biol Regul Homeost Agents; 2003 Nov 15; 17(4):322-6. PubMed ID: 15065761
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Neuroendocrine aspects in monitoring of dopaminergic drugs in man.
    Hietala J, Koulu M, Scheinin M, Syvälahti E.
    Methods Find Exp Clin Pharmacol; 1985 Aug 15; 7(8):451-4. PubMed ID: 3935892
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of apomorphine on cognitive performance and sensorimotor gating in humans.
    Schellekens AF, Grootens KP, Neef C, Movig KL, Buitelaar JK, Ellenbroek B, Verkes RJ.
    Psychopharmacology (Berl); 2010 Jan 15; 207(4):559-69. PubMed ID: 19834690
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Multihormonal responses to apomorphine in mental illness.
    Mokrani MC, Duval F, Crocq MA, Bailey PE, Macher JP.
    Psychoneuroendocrinology; 1995 Jan 15; 20(4):365-75. PubMed ID: 8532820
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Psychooncology and cancer progression-related alterations of pleasure-associated neurochemical system: Abnormal neuroendocrine response to apomorphine in advanced cancer patients.
    Lissoni P, Malugani F, Manganini V, Ardizzoia A, Gardani G, Bartolacelli E, Messina G, Tancini G.
    Neuro Endocrinol Lett; 2003 Jan 15; 24(1-2):50-3. PubMed ID: 12743532
    [Abstract] [Full Text] [Related]

  • 13. Growth hormone response to apomorphine in obsessive-compulsive disorder.
    Pitchot W, Hansenne M, Moreno AG, Ansseau M.
    J Psychiatry Neurosci; 1996 Nov 15; 21(5):343-5. PubMed ID: 8973055
    [Abstract] [Full Text] [Related]

  • 14. Effects of short-term administration of valproate on serotonin-1A and dopamine receptor function in healthy human subjects.
    Delva NJ, Brooks DL, Franklin M, al-Said K, Hawken ER, Merali Z, Lawson JS, Ravindran AV.
    J Psychiatry Neurosci; 2002 Nov 15; 27(6):429-37. PubMed ID: 12491576
    [Abstract] [Full Text] [Related]

  • 15. Sublingual apomorphine for the treatment of erectile dysfunction.
    Mulhall JP.
    Expert Opin Investig Drugs; 2002 Feb 15; 11(2):295-302. PubMed ID: 11829718
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The effects of dieting and weight loss on neuroendocrine responses to tryptophan, clonidine, and apomorphine in volunteers. Important implications for neuroendocrine investigations in depression.
    Goodwin GM, Fairburn CG, Cowen PJ.
    Arch Gen Psychiatry; 1987 Nov 15; 44(11):952-7. PubMed ID: 3675135
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease.
    van Laar T, Neef C, Danhof M, Roon KI, Roos RA.
    Mov Disord; 1996 Nov 15; 11(6):633-8. PubMed ID: 8914088
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.